Reply to López-Campos et al.: Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect

Detalles Bibliográficos
Autores principales: Lipson, David A., Han, MeiLan K., Wise, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2021
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017567/
https://www.ncbi.nlm.nih.gov/pubmed/33444516
http://dx.doi.org/10.1164/rccm.202012-4494LE
_version_ 1783674076725772288
author Lipson, David A.
Han, MeiLan K.
Wise, Robert
author_facet Lipson, David A.
Han, MeiLan K.
Wise, Robert
author_sort Lipson, David A.
collection PubMed
description
format Online
Article
Text
id pubmed-8017567
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Thoracic Society
record_format MEDLINE/PubMed
spelling pubmed-80175672021-04-02 Reply to López-Campos et al.: Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect Lipson, David A. Han, MeiLan K. Wise, Robert Am J Respir Crit Care Med Correspondence American Thoracic Society 2021-04-01 2021-04-01 /pmc/articles/PMC8017567/ /pubmed/33444516 http://dx.doi.org/10.1164/rccm.202012-4494LE Text en Copyright © 2021 by the American Thoracic Society https://creativecommons.org/licenses/by-nc-nd/4.0/This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ). For commercial usage and reprints, please contact Diane Gern (dgern@thoracic.org).
spellingShingle Correspondence
Lipson, David A.
Han, MeiLan K.
Wise, Robert
Reply to López-Campos et al.: Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect
title Reply to López-Campos et al.: Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect
title_full Reply to López-Campos et al.: Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect
title_fullStr Reply to López-Campos et al.: Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect
title_full_unstemmed Reply to López-Campos et al.: Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect
title_short Reply to López-Campos et al.: Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect
title_sort reply to lópez-campos et al.: triple-therapy trials for chronic obstructive pulmonary disease: methodological considerations in the mortality effect
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017567/
https://www.ncbi.nlm.nih.gov/pubmed/33444516
http://dx.doi.org/10.1164/rccm.202012-4494LE
work_keys_str_mv AT lipsondavida replytolopezcamposetaltripletherapytrialsforchronicobstructivepulmonarydiseasemethodologicalconsiderationsinthemortalityeffect
AT hanmeilank replytolopezcamposetaltripletherapytrialsforchronicobstructivepulmonarydiseasemethodologicalconsiderationsinthemortalityeffect
AT wiserobert replytolopezcamposetaltripletherapytrialsforchronicobstructivepulmonarydiseasemethodologicalconsiderationsinthemortalityeffect

Ejemplares similares